Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rozanolixizumab in pediatric generalized myasthenia gravis
2022-502075-34-00Phase 3Authorised
- Sponsor
- UCB
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Primary endpoints: Occurrence of serious treatment-emergent adverse events, Occurrence of treatment-emergent adverse events leading to permanent withdrawal of investigational medicinal product and 1 more. Planned start Oct 2024; status: authorised.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2022-502075-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502075-34-00.